In late stage PCa, when hormonal therapeutic avenues become ineffectual, the PI3/AKT pathway (activated by PTEN loss) remains an active therapeutic intervention avenue, targeting one of the downstream PI3/AKT substrates namely the mammalian target of rapamycin (mTOR). This evidence concerns the gene MTOR and posterior cortical atrophy.